Uysal Pınar, Erge Duygu
Department of Pediatrics, Division of Pediatric Allergy and Immunology, Adnan Menderes University School of Medicine, Aydın, Turkey.
Turk Pediatri Ars. 2018 Dec 1;53(4):250-254. doi: 10.5152/TurkPediatriArs.2016.4042. eCollection 2018 Dec.
Omalizumab is a recombinant humanized monoclonal anti-IgE antibody. Until now, the efficiency of omalizumab in chronic spontaneous urticaria has been demonstrated in several studies. However in the literature, data showing the efficiency of omalizumab in different phenotypes of H1-antihistamine-refractory chronic urticaria are limited. In this report, the success of treatment with omalizumab from the first dose is presented in three patients with chronic spontaneous urticaria, chronic autoimmune urticaria, and idiopathic angioedema, who were unresponsive to high-dose H1-antihistamine. The symptoms of all patients resolved with the first dose of omalizumab and no symptom recurrence developed during the follow-up period. In this case presentation, the effective treatment of different phenotypes of H1-antihistamine-refractory chronic urticaria is discussed with a review of the literature.
奥马珠单抗是一种重组人源化抗IgE单克隆抗体。到目前为止，多项研究已证实奥马珠单抗治疗慢性自发性荨麻疹的有效性。然而，在文献中，显示奥马珠单抗对不同表型的H1抗组胺药难治性慢性荨麻疹有效的数据有限。本报告介绍了3例慢性自发性荨麻疹、慢性自身免疫性荨麻疹和特发性血管性水肿患者，他们对高剂量H1抗组胺药无反应，但使用奥马珠单抗治疗从首剂开始即取得成功。所有患者的症状在首剂奥马珠单抗治疗后均得到缓解，且在随访期间无症状复发。在本病例报告中，结合文献回顾讨论了对不同表型的H1抗组胺药难治性慢性荨麻疹的有效治疗。
